NCT06783127 Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
| NCT ID | NCT06783127 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Santa Chiara Hospital |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Eligibility Criteria
Inclusion Criteria: BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice Exclusion Criteria: Olaparib treatment in a clinical trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06783127 clinical trial?
This trial is open to male participants only, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06783127 currently recruiting?
Yes, NCT06783127 is actively recruiting participants. Contact the research team at orazio.caffo@apss.tn.it for enrollment information.
Where is the NCT06783127 trial being conducted?
This trial is being conducted at Naples, Italy, Trento, Italy.
Who is sponsoring the NCT06783127 clinical trial?
NCT06783127 is sponsored by Santa Chiara Hospital. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.